Precision BioSciences (NASDAQ:DTIL) Rating Reiterated by HC Wainwright

HC Wainwright reiterated their buy rating on shares of Precision BioSciences (NASDAQ:DTIL – Get Rating) in a research report report published on Wednesday morning, Benzinga reports. HC Wainwright currently has a $17.00 price objective on the stock. HC Wainwright also issued estimates for Precision BioSciences’ Q4 2023 earnings at ($0.21) EPS, FY2023 earnings at ($0.87) EPS, FY2024 earnings at ($0.60) EPS, FY2026 earnings at $0.37 EPS and FY2027 earnings at $0.73 EPS.

DTIL has been the topic of a number of other reports. BTIG Research dropped their price target on Precision BioSciences to $6.00 in a research note on Tuesday, November 15th. BMO Capital Markets downgraded Precision BioSciences from an outperform rating to a market perform rating and dropped their price target for the stock from $7.00 to $4.00 in a research note on Monday, March 13th.

Precision BioSciences Stock Performance

Shares of DTIL opened at $0.87 on Wednesday. The business’s fifty day simple moving average is $1.16 and its two-hundred day simple moving average is $1.29. The company has a current ratio of 3.34, a quick ratio of 3.34 and a debt-to-equity ratio of 0.37. Precision BioSciences has a 12 month low of $0.84 and a 12 month high of $3.64. The company has a market cap of $96.83 million, a price-to-earnings ratio of -0.62 and a beta of 1.45.

Hedge Funds Weigh In On Precision BioSciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. Quantbot Technologies LP lifted its position in Precision BioSciences by 3,915.4% during the third quarter. Quantbot Technologies LP now owns 20,077 shares of the company’s stock valued at $26,000 after purchasing an additional 19,577 shares in the last quarter. Acuta Capital Partners LLC purchased a new position in Precision BioSciences during the second quarter valued at $3,281,000. UBS Oconnor LLC lifted its position in Precision BioSciences by 11.9% during the third quarter. UBS Oconnor LLC now owns 492,517 shares of the company’s stock valued at $640,000 after purchasing an additional 52,517 shares in the last quarter. Penserra Capital Management LLC lifted its position in Precision BioSciences by 463.2% during the third quarter. Penserra Capital Management LLC now owns 98,175 shares of the company’s stock valued at $127,000 after purchasing an additional 80,743 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its position in Precision BioSciences by 14.3% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 116,777 shares of the company’s stock valued at $152,000 after purchasing an additional 14,626 shares in the last quarter. 50.50% of the stock is currently owned by hedge funds and other institutional investors.

Precision BioSciences Company Profile

(Get Rating)

Precision BioSciences, Inc is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases.